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Abstract 
Epidemiological studies have suggested an inverse correlation between high density 
lipoprotein (HDL) cholesterol levels and the risk of cardiovascular disease. HDLs promote 
reverse cholesterol transport (RCT) and possess several putative atheroprotective functions, 
associated to the anti-inflammatory, anti-thrombotic and anti-oxidant properties as well as to 
the ability to support endothelial physiology.  
The assumption that increasing HDL-C levels would be beneficial on cardiovascular disease 
(CVD), however, has been questioned as, in most clinical trials, HDL-C-raising therapies did 
not result in improved cardiovascular outcomes. These findings, together with the observations 
from Mendelian randomization studies showing that polymorphisms mainly or solely associated 
with increased HDL-C levels did not decrease the risk of myocardial infarction, shift the focus 
from HDL-C levels toward HDL functional properties. Indeed, HDL from atherosclerotic patients 
not only exhibit impaired atheroprotective functions but also acquire pro-atherogenic 
properties and are referred to as “dysfunctional” HDL; this occurs even in the presence of 
normal or elevated HDL-C levels. Pharmacological approaches aimed at restoring HDL 
functions may therefore impact more significantly on CVD outcome than drugs used so far to 
increase HDL-C levels. Aims of this review is to discuss the pathological conditions leading to 
the formation of dysfunctional HDL and their role in atherosclerosis and beyond. 
Keywords high density lipoprotein; dysfunctional HDL; HDL quality; HDL subfractions; 
atherosclerosis; cardiovascular disease;  
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Introduction 
Epidemiological studies have suggested an inverse relationship between high density 
lipoprotein (HDL) cholesterol (HDL-C) levels and the risk of atherosclerotic cardiovascular 
disease [1]. The atheroprotective role of HDL is related to their key function in reverse 
cholesterol transport (RCT), as well as a number of additional potentially favorable properties 
including anti-inflammatory, antithrombotic, and antioxidant effects (Figure 1) [2]. 
Accordingly, several efforts to develop drugs to increase HDL-C levels have been undertaken 
[3]. These approaches, including those aimed at increasing apolipoprotein A-I (apoA-I) levels, 
have shown some beneficial effects either in preclinical studies [4-6] or in patients with 
coronary heart disease (CHD) [7-10]. However, recent clinical trials evaluating the effects of 
HDL-C-raising therapies have failed to demonstrate a benefit on cardiovascular outcomes [11-
13], with the exception of the recent REVEAL study on anacetrapib [14]. In addition, Mendelian 
randomization analyses have shown that single nucleotide polymorphisms that exclusively 
associate with higher HDL-C levels do not associate with a reduced risk of myocardial infarction 
[15]. These findings, together with the observation that the inverse relationship between HDL-
C levels and cardiovascular risk is present only in healthy subjects or in patients without CHD, 
while it is significantly weakened in patients with cardiovascular disease [16, 17], raised the 
question of whether HDL-C level is the right parameter to follow in clinic, and set the stage for 
testing the clinical relevance of changes in HDL function [18-20]. This possibility is supported 
by several observations: i) increased concentrations of lecithin-cholesterol acyltransferase 
(LCAT), which are associated with increased HDL-C levels, do not necessarily associate with 
atheroprotection and, conversely, LCAT deficiency, characterized by lower levels of HDL-C, 
does not associate with increased risk of atherosclerosis [21]. ii) HDL cholesterol efflux 
capacity is inversely associated with the incidence of cardiovascular events in a population-
based cohort free from cardiovascular disease, an association that persists even after 
adjustment for HDL-C levels or HDL particle concentrations [22] and predicts atherosclerotic 
burden better than HDL-C levels [22-25]. iii) The use of apoA-I mimetic peptides may improve 
HDL activities without changing its mass [26]. A recent study reported that the administration 
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of the apoA-I mimetic peptide D-4F reduced the HDL-inflammatory burden in patients at high 
CHD risk, suggesting that this approach might result in improved HDL functions [27]. iv) Very 
high HDL-C levels and very large HDL particles associate with no cardiovascular benefit or 
even an increased risk of coronary artery disease (CAD) [28-30]. A possible explanation for 
these findings is related to the presence of “dysfunctional” HDL, i.e. HDL particles that have 
lost their atheroprotective functions and may be even pro-atherogenic (Figure 1). It is 
conceivable, therefore, that measuring HDL-C levels, although will capture the relative 
contribution of “protective HDL” not always will inform on their absolute levels or activity, and 
this might explain the observed disconnection of these measurements. 
In this review we will discuss the biological effects of dysfunctional HDL and their possible 
relationship with atherosclerotic related diseases. 
HDL STRUCTURE, COMPOSITION AND FUNCTIONS 
HDL family includes both discoidal and spherical particles, heterogeneous in density, shape, 
size and electrophoretic mobility, which undergo continuous remodeling processes mediated by 
lipolytic enzymes and lipid transfer proteins. ApoA-I is the main apoprotein of HDL (70%) and 
plays relevant functions either as structural or functional protein [31]. ApoA-II is the second 
major apolipoprotein of HDL (15-20% of total proteins) and has the ability to displace apoA-I 
from HDL. Increased levels of apoA-II associated-HDL therefore dampen the function of apoA-
I-containing HDL on reverse cholesterol transport, scavenger receptor class B type I (SR-BI) 
dependent hepatic cholesterol catabolism as well as the activity of enzymes involved in HDL 
metabolism [32]. However, HDL carry additional apoproteins (including apoE, apoCs, apoA-IV, 
apoA-V, apoJ, apoF, apoM, apoL1), enzymes involved in lipid metabolism (including LCAT and 
phospholipid transfer protein [PLTP]) as well as antioxidant enzymes, such as paraoxonase 1 
(PON1), platelet-activating factor-acetyl hydrolase (PAF-AH) and glutathione selenoperoxidase 
(GSPx), acute phase response proteins (including serum amyloid A [SAA]) and complement 
components [31]. 
Based on surface charge and shape, HDL may be distinguished in pre-ß-migrating and -
migrating particles. Pre-ß particles are mainly nascent discoidal lipoproteins containing apoA-I, 
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phospholipids and free cholesterol and a very small core of neutral lipids, while -migrating 
particles are “mature” quasi-spherical lipoproteins containing a hydrophobic core of cholesteryl 
esters (CE) and triglycerides (TG). Based on their density, HDL can also be classified as the 
large lipid-rich HDL2 and the small dense HDL3 [31]. HDL2 and HDL3 can be further 
subfractionated into 5 distinct subpopulations by native gradient gel electrophoresis based on 
their size, resulting in HDL2a and 2b and HDL3a, 3b and 3c [31]. Finally, HDL can be 
separated according to their apoprotein content into particles containing only apoA-I (LpA-I) or 
both apoA-I and apoA-II (LpA-I:A-II) [31] (Figure 2). Due to the different methodologies used 
to measure HDL subclasses, it is difficult to find relations among them. For this reason, a 
classification of HDL based on density and size has been proposed, leading to the identification 
of five HDL subclasses (very large, large, medium, small and very small HDL) which should 
help to identify a relationship between these subclasses and cardiovascular risk [33] (Figure 
2). 
HDL particles differ also for their proteome and lipidome, with some subfractions carrying 
specific and distinct components not present in others. For example, HDL3c particles carry 
predominantly some proteins (including apoJ, PON1, PLTP, PAF-AH) [34] associated with its 
high antioxidant capacity. Instead, apoE and apoCs are preferentially carried by HDL2 [35]; 
these apoE-rich, large HDL particles are involved in the reverse cholesterol transport process 
through the interaction with scavenger receptor type B class I (SR-BI) and ATP-binding 
cassette transporter G1 (ABCG1) [36]. Again, sphingosine-1-phosphate (S1P), a minor 
bioactive lipid, is associated mainly with HDL3 particles [37].  
HDL possess several potential atheroprotective functions (Figure 1). The most studied 
property of HDL is its role in RCT, the process by which excess cholesterol is believed to be 
transported from the peripheral tissues to the liver for excretion [38-40]. This process involves 
two main steps (Figure 3). During the first step, lipid-free or lipid-poor apoA-I (referred to as 
pre-ß HDL) accepts cholesterol from membranes of lipid-loaded cells of the arterial wall 
through the interaction with ATP-cassette binding transporter A1 (ABCA1). Circulating LCAT 
then esterifies free cholesterol and generates more mature HDL particles (-particles) 
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containing a lipid core composed by highly hydrophobic lipids (mainly cholesteryl esters, CE) 
and that can further accept cholesterol from cells following the interaction with ABCG1, ABCG4 
[39, 41, 42] or SR-BI [43]. RCT is then completed by a third step during which CE are 
delivered to the liver; this occurs by two different mechanisms: 1) directly, through the 
interaction of hepatic SR-BI and mature HDL particles, 2) indirectly, following the cholesteryl 
ester transfer protein (CETP)-mediated transfer of CE from HDL particles to VLDL and LDL and 
subsequent clearance by hepatic LDLR [40].  
HDL possess anti-inflammatory properties [44, 45]. Experimental evidence demonstrates 
that HDL inhibit the endothelial activation induced by inflammation: the expression of surface 
adhesion molecules and chemoattractant proteins is reduced [46-53], thus decreasing the 
recruitment of monocytes, dendritic cells and T lymphocytes at sites of inflammation [54] and 
controlling the immune response. HDL may also act on circulating leukocytes to limit 
inflammation, for example by inhibiting the activation of CD11b, a surface protein involved in 
monocytes adhesion [55]. In addition, HDL inhibit the inflammasome activation and its 
downstream inflammatory cytokines through several mechanisms, thus reducing inflammation 
[56]. Different HDL subfractions exhibit different anti-inflammatory properties, being small 
dense HDL3 more efficient than large HDL2 in inhibiting the expression of endothelial adhesion 
molecules [57]. HDL3, probably due to its unique proteome [34], possess the highest ability to 
prevent LDL oxidation as well as the OxLDL-induced apoptosis of endothelial cells [58, 59]. 
Small dense HDL3 remove oxidized lipids from lipoproteins and cellular membrane more 
efficiently that large HDL2, an effect probably related to a reduced content in sphingomyelin 
and free cholesterol [37] which increases the fluidity of the surface lipid monolayer and 
facilitates the incorporation of oxidized lipids [60]. Spherical HDL have a higher inhibitory 
effect compared with discoidal particles [61]. Both proteins and lipids associated with HDL 
contribute to its anti-inflammatory activity. Modifications of HDL, such as glycation or 
oxidation, impair the anti-inflammatory capacity of HDL and instead generate particles with 
pro-inflammatory activity [62-65]. Furthermore, during an inflammatory response, HDL may 
undergo profound modifications both in mass and composition. Although it is difficult to 
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establish whether changes in plasma lipoproteins simply reflect the severity of disease or can 
directly modify the host response to inflammation, low HDL-C levels inversely correlate with 
the severity of septic disease and associate with an exaggerated systemic inflammatory 
response [66]. Also in healthy subjects low HDL levels is associated with increased 
inflammatory response on endotoxin challenge compared to subjects with normal or high HDL 
levels [67], without differences in the HDL proteome [68]. 
By removing excess cholesterol from macrophages following the interaction with ABCA1 and 
ABCG1, apoA-I and HDL reduce the macrophage expression of pro-inflammatory mediators, 
including MCP-1 and CD11b and inhibits the proliferation of lymphocytes [69]. In addition, the 
removal of membrane cholesterol alter the composition of lipid rafts, membrane microdomains 
involved in several biological processes, and contribute to the tuning of the innate and the 
adaptive immune response, globally resulting in reduced inflammatory activity of macrophages 
and reduced lymphocyte activation [69-71].  
Beside a direct anti-inflammatory effect, HDL may counteract some of the pro-atherogenic 
effects of oxidized LDL (OxLDL); as example, HDL were shown to inhibit modified-LDL-induced 
monocyte-endothelium interaction [72], to prevent OxLDL-induced inhibition of eNOS 
activation [73], as well as OxLDL-induced platelet aggregation and adhesion [74], endothelial 
cell death [75] and reactive oxygen species increase [76]. HDL prevent the effects of 
electronegative LDL naturally occurring in the plasma, whose concentration is increased in 
atherosclerosis-associated diseases, which exhibit a higher susceptibility to aggregation and 
may exert inflammatory effects [77]. HDL and apoA-I can also prevent the oxidation of LDL 
[78, 79] by binding and removing lipid hydroperoxides [80, 81], as well as LDL aggregation by 
interacting with hydrophobic domains of the lipoprotein thus blocking the interactions that lead 
to aggregation [82]. Besides apoA-I, other HDL-associated apolipoproteins contribute to the 
anti-oxidant function, including apoE2 isoform [83] and apoA-IV [84]. HDL carry additional 
antioxidant enzymes able to prevent lipid oxidation or degrade lipid hydroperoxides, including 
PON1 and PAF-AH [85].  
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HDL play a role also on endothelial function by stimulating the production of NO and 
prostacyclin (PGI2) in these cells [86]. The generation of NO occurs following the interaction of 
HDL with endothelial SR-BI [87] and subsequent activation of Akt, which in turn activates 
endothelial NO synthase (eNOS), which is localized in specialized membrane microdomains 
enriched in cholesterol named caveolae [88]. HDL also maintain the lipid environment in 
caveolae, thus promoting eNOS function [89] and the cyclooxygenase-2/PGI2 synthase 
coupling [90]. ApoA-I seems to play a relevant role in the vasodilatory effect of HDL [91], but 
also S1P and PON1 contribute to the ability of HDL to stimulate NO production [92-94]. Both 
HDL2 and HDL3 (HDL2>HDL3) induce PGI2 secretion from endothelial cells; on the other hand, 
HDL2 inhibit the release of the potent vasoconstrictor thromboxane A2 (TXA2), while HDL3 
induce its release [95]. The ratio PGI2/TXA2 suggests a more favorable vasodilatory effect for 
the HDL2 subfraction. 
Endothelial apoptosis may result in an increased permeability of vascular endothelium; in 
addition, dysregulated apoptosis of atherosclerotic plaque cells may be an unfavorable process 
leading to plaque instability [96, 97], and HDL may attenuate this process. In fact HDL inhibit 
macrophage [98] as well as endothelial cell apoptosis induced by different stimuli [59, 75, 99, 
100]. ApoA-I and HDL-associated lysosphingolipids are the major components responsible for 
this effect [98, 99, 101]. HDL inhibits the apoptosis induced by several stimuli in endothelial 
cells [59, 99], macrophages [102] and other cell types. Both proteins and lipids contribute to 
the antiapoptotic effect of HDL. ApoA-I is the major protein involved in this process [59], but 
also HDL-associated lysosphingolipids [37, 101, 103, 104] and PON1 play a role as well [105]. 
Small dense HDL3c have been shown to be most potent anti-apoptotic particles [59, 106]. On 
the other hand, plasma HDL-C levels positively correlates with the number of endothelial 
progenitor cells (which play a role in endothelial injury-repair process), evaluated as 
endothelial colony-forming units in culture [107]. 
HDL possess also anti-thrombotic properties; in vitro, HDL inhibit platelet activity and the 
expression of endothelial tissue factor induced by thrombin [108, 109]; furthermore, HDL 
stimulate the synthesis of prostacyclin, which inhibit platelet aggregation, by supplying 
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arachidonic acid and inducing the expression of cyclooxygenase-2 [46, 90, 110]. In addition, 
HDL and apoA-I inhibit the self-association of von Willebrand factor, a process involved in the 
binding of platelet and formation of occlusive thrombi in small vessels [111].  
 
 
PATHOPHYSIOLOGICAL MECHANISMS OF DYSFUNCTIONAL HDL GENERATION 
DEFECTIVE HDL REMODELLING  
Several enzymes, proteins and receptors are involved in the metabolism and remodeling of 
HDL; mutations in the genes encoding for these proteins have been associated with changes in 
HDL-C plasma levels as well as in the composition and function of HDL particles [112].  
Under physiological conditions, LCAT plays a relevant role in HDL metabolism by mediating 
the esterification of free cholesterol (causing an increase in HDL size), which is then 
transferred from HDL to TG-rich lipoproteins by the action of CETP (Figure 3). The activity of 
CETP leads to the reduction of HDL-C levels and HDL particle size. In this way, following the 
activity of LCAT, the newly formed pre-ß particles are converted into mature, spherical -
migrating HDL. The latter may be converted back to pre-ß-HDL by the action of CETP and 
other lipases: CETP mediates the transfer of CE between HDL and TG-rich lipoproteins, 
generating TG-rich HDL, which can be further hydrolyzed by hepatic lipase (HL) to small, TG-
rich HDL particles (Figure 3). The joint action of CETP and HL promotes reduction in HDL size, 
formation of lipid-poor HDL particles, and shedding from HDL of lipid-free apoA-I, which can 
restart the lipidation cycle (Figure 3). Another critical enzyme in the metabolism of HDL is 
endothelial lipase (EL), synthesized and secreted by endothelial cells and involved in the 
hydrolysis of HDL phospholipids. Its activity results in the destabilization of HDL particle, 
shedding of poorly lipidated apoA-I and hepatic uptake of the remodeled HDL particle [113] 
(Figure 3). Thus, this enzyme serves as a negative regulator of plasma HDL-C levels, although 
its role in atherosclerosis is still unclear. While in vitro EL-mediated generation of lipid-poor 
apoA-I increased cholesterol efflux capacity, in vivo EL overexpression reduced HDL without 
apoA-I generation and with impaired serum cholesterol efflux capacity[114].  
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When the activity of one of these proteins involved in HDL metabolism is altered, the 
process of maturation and remodeling of HDL is affected, leading to the formation of 
“dysfunctional” lipoproteins. The deficiency of LCAT-mediated esterification of free cholesterol 
leads to defective HDL maturation, characterized by the accumulation of pre-ß-particles [115] 
(Figure 4). Reduced LCAT activity may be due to either mutations in the gene encoding for this 
protein or to pathological conditions, such as metabolic syndrome, type 2 diabetes or chronic 
kidney disease [116-118]. Genetic variants of LCAT reducing the activity of this protein are 
associated with reduced HDL-C plasma levels and alterations in HDL structure and particle 
distribution, with a selective depletion of large -particles and accumulation of small preβ-HDL 
which also contain apoA-II [119]. These alterations in HDL particle distribution translated into 
an improved ability of serum from LCAT deficient patients to efflux cholesterol through the 
ABCA1 transporter [120]. A similar pattern was observed in patients with metabolic syndrome, 
who exhibited a slightly reduced LCAT mass, increased pre-ß HDL and increased ABCA1-
mediated cholesterol efflux [116]. This was accompanied by reduction of HDL particle size and 
number and triglyceride enrichment [116]. In spite of this effect, the impact of LCAT deficiency 
on atherosclerosis is debated with either increased or decreased intima-media thickness (IMT) 
reported [120, 121]. 
The activity of CETP, which remodels HDL particles and increases LDL-C and VLDL-C levels 
(Figure 5), is increased in some conditions, such as hyperlipidemia. Genetic studies and a 
Mendelian randomization analysis have suggested a reduced cardiovascular risk in subjects 
carrying polymorphisms associated with reduced CETP activity [15, 122-124]. Subjects with 
mutations leading to CETP deficiency exhibit, in fact, increased levels of HDL-C, lower levels of 
LDL-C and a reduced incidence of CHD [125]. In particular, CETP-deficient subjects had 
increased levels of large HDL2 particles associated with a higher SR-BI/ABCG1-mediated 
cholesterol efflux capacity compared with control subjects [126, 127]. In addition, HDL isolated 
from CETP-deficient subjects exhibit normal anti-inflammatory and anti-oxidant properties 
[128, 129], although they are less effective in inducing NO production, probably due to a 
reduced S1P content [128], or to a reduced ability to interact with SR-BI [130]. The hypothesis 
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that pharmacological inhibition of CETP might mimic the CETP-deficient phenotype, resulting in 
an overall improved HDL function and reduced cardiovascular risk, has been challenged by the 
results of clinical trials, which failed to show a cardiovascular benefit despite significant HDL-C 
level increase [12, 13, 131]. An exception is represented by anacetrapib that reduced the 
incidence of major coronary events compared with placebo in atorvastatin-treated patients 
with atherosclerotic vascular disease [14]. However, as anacetrapib also significantly reduced 
LDL-C levels, it is likely that the observed cardiovascular benefit depends on this effect [132]. 
A post-hoc analysis of 2 large prospective study, however, suggested that very large HDL 
particles, which are formed upon CETP inhibition, are associated with higher risk of 
cardiovascular events despite apoA-I remains negatively associated to CAD risk [29]. Recently 
it has been shown that, in CETP transgenic mice, cholesterol efflux as well as PON1 activity 
were significantly increased and reactive oxygen species decreased by evacetrapib, while 
anacetrapib had no effect, despite similar effects on lipids [133]. As a result, anacetrapib 
worsened endothelium-dependent acetylcoline-induced vasorelaxation while evacetrapib had 
no effect [133]. Furthermore, the ACCENTUATE study with evacetrapib [134] showed that, 
although the treatment increased cholesterol efflux capacity, it also generated HDL particles 
with increased apoC-III content. ApoC-III-enriched HDL are less functional [135, 136] and 
might perhaps provide apoC-III to the arterial wall, which may trigger an inflammatory process 
in endothelial cells, characterized by increased expression of pro-inflammatory cytokines and 
increased adhesion of monocytes, as well as alterations of endothelial apoptosis [135, 137-
139]. These findings suggest that, although effective in improving the overall lipid profile, 
pharmacological CETP inhibition might not associate to a vascular protective effect. 
 
MYELOPEROXIDASE-INDUCED MODIFICATION OF HDL 
One major pathway responsible for the generation of dysfunctional HDL involves 
myeloperoxidase (MPO), a heme protein overexpressed in human atherosclerotic lesions where 
it colocalizes also with macrophages [140]. Locally this enzyme produces hypoclorous acid 
(HOCl) and peroxynitrite (ONOO-) which convert free and protein-bound tyrosine residues to 3-
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chlorotyrosine and 3-nitrotyrosine [140]. An increased expression of MPO has been observed 
during the progression of atherosclerotic lesion into atherosclerotic plaque, with a maximal 
expression immediately before plaque rupture [141, 142], which may suggest this enzyme as 
a marker of unstable advanced plaque. Accordingly, MPO was detected within atherosclerotic 
plaques of patients with acute coronary syndrome, in which was shown to form complexes with 
apoA-I [143]. Circulating HDL isolated from patients with cardiovascular disease, acute 
coronary syndrome or diabetes present high levels of both 3-chlorotyrosine and 3-nitrotyrosine 
[144-147]. Chlorinated and nitrated adducts have been detected in human atherosclerotic 
lesions where they co-localize with macrophages [144, 145, 148]. In vitro MPO chlorinates and 
nitrates tyrosine 192 residue of apoA-I [149, 150], a modification detected also in HDL isolated 
from human atherosclerotic tissues or diabetic subjects [146, 151]. The oxidation of this 
specific tyrosine residue results in an impaired ability of HDL to promote ABCA1-mediated 
cholesterol [144, 146, 150]. In vivo, the injection of MPO-oxidized apoA-I resulted in a 
significantly lower RCT compared to mice injected with native HDL [152]. Atherosclerotic 
plaques from mice injected with MPO-oxidized apoA-I were not different in size, but presented 
increased macrophage and lipid accumulation and reduced collagen content [152]. The latter 
observation is in line with the ability of chlorinated and nitrated HDL to inhibit SMC migration 
and exhibit a reduced ability to stimulate SMC proliferation, without significant effects on SMC 
apoptosis [153]. Furthermore, in experimental models of carotid stenosis, the injection of 
chlorinated or nitrated HDL resulted in increased neointima/media ratio and reduced SMC 
positive staining cells in the fibrous cap compared to native HDL-treated mice, thus suggesting 
that MPO-HDL might increase the vulnerability index of the plaque [153]. 
In humans, serum MPO/HDL particle ratio was directly associated to incident cardiovascular 
disease (CVD) in a population-based cohort free from CVD at baseline [154]. The observation 
that MPO/HDL particle ratio was directly associated with high-sensitivity C-reactive protein and 
IL-18, and inversely associated with PON1 arylesterase activity [155] further linked MPO-HDL 
with increased vascular inflammation.  
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HDL GLYCATION 
An increased generation of advanced glycation end products in a hallmark of diabetes. Non-
enzymatic glycation may occur under conditions of chronic hyperglycemia (poorly controlled 
diabetes), leading to alterations of HDL composition (lipids, apoproteins and enzymes) and 
functionality [156]. In vitro, the exposure of endothelial cells to glycated HDL induces 
apoptosis by triggering mitochondrial dysfunction [157] and increases oxidative stress [158]. 
In addition, glycated HDL are less effective in counteracting the inhibitory effect of OxLDL on 
endothelium-dependent vasorelaxation [159] and trigger vascular smooth muscle cell 
proliferation and migration [160]. The glycation of apoA-I alters the conformation of the 
apoprotein in regions that are critical for LCAT activation [161], reduces its ability to promote 
cholesterol efflux from macrophages and to inhibit the expression of adhesion molecules and 
ROS formation [62, 162]. In humans, apoA-I glycation is associated with the severity of CAD 
and coronary artery plaque progression in patients with type 2 diabetes [163, 164] and with a 
significantly reduced apoA-I half-life [165]. Furthermore, HDL isolated from type 2 diabetic 
patients exhibited a reduced ability to catabolize membrane lipid hydroperoxides [166], to 
reverse the OxLDL-induced inhibition of vasodilation [167] and overall a reduced anti-
inflammatory activity [168].  
Altogether these observations suggest that modification of HDL in diabetes may significantly 
impair their athero-protective functions and may contribute to the increased cardiovascular 
risk.  
 
HDL ALTERATIONS DURING INFECTION/INFLAMMATION 
Lipid metabolism and lipoprotein composition are altered during infection, and the reduction 
of plasma HDL-C levels is associated with changes in HDL composition and size. ApoA-I and 
phospholipids are reduced while serum amyloid A (SAA) and secretory phospholipase A2 
(sPLA2) are increased in acute phase HDL [71, 169]. These changes appear to be associated 
with a protection toward infections and together with other immunomodulatory activities 
support the evolutionary conserved function of HDL in the immune response [70, 170].  
14 
 
Following infection, total HDL particle number does not change, while a significant decrease 
in the number of small and medium size particles is observed [171]. SAA rapidly associates to 
HDL and promotes the displacement of apoA-I; thus becoming the main protein of acute-phase 
HDL [172, 173] while when the inflammatory triggers are removed, SAA is cleared rapidly over 
∼72 h, [174] and is slowly replaced by apoA-I during recovery [175]. In parallel, during 
infection, the content of other HDL associated proteins (PON1, PAF-AH) is decreased, while 
ceruloplasmin content increases, with a net effect of reduced anti-oxidant capacity [176, 177] 
and increased content of pro-atherogenic lipids [178, 179] (Table 1). Changes in HDL 
remodeling enzymes including the increase of endothelial lipase [180] and secretory 
phospholipase A2 [171] and the decrease of CETP and LCAT [66, 171] contribute to alter HDL 
lipid composition and is paralleled by the reduction of functionality [171, 181, 182], including 
the ability to promote reverse cholesterol transport (Table 1)[183].  
These observations indicate a role of HDL in the protection against sepsis and suggest the 
possibility that SAA-HDL could be a marker of an efficient immune response. Nevertheless a 
SAA-ApoA-I crosslink was observed in acute phase HDL which was proposed to contribute to 
the amyloidogenic potential of these proteins [184], further studies are needed to clarify this 
issue. 
In summary, acute infections represent a conditions where HDL are rapidly and largely 
rearranged and represent a disease condition where pharmacological approaches aimed at 
improving HDL composition rather than HDL-C levels might play a role. Alterations in the 
function/composition of HDL particles may also result in the impairment of immune functions. 
Vice versa patients with autoimmune diseases (such as systemic lupus erythematosus or 
rheumatoid arthritis), which are at increased cardiovascular risk [185], present altered HDL 
functionality, including reduced cholesterol efflux capacity, reduced antioxidant properties, and 
increased pro-inflammatory index [186-192] (Table 1).  
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ALTERATIONS OF ATHEROPROTECTIVE PROPERTIES OF HDL IN CARDIOVASCULAR 
DISEASE 
Impaired cholesterol efflux capacity of HDL has been related to structural changes of HDL 
components; in particular, alterations of apoA-I, primarily due to oxidative modifications, 
account for this effect owing to a reduced ability of oxidized apoA-I to induce ABCA1-mediated 
cholesterol efflux in vitro [144, 150, 193-195]. Thus, HDL isolated from patients with 
cardiovascular disease have been shown to exhibit a reduced cholesterol efflux potential. This 
was observed with HDL isolated from patients with acute coronary syndrome or CAD patients 
compared with healthy subjects, despite similar levels of plasma HDL-C, which suggests an 
altered functionality of HDL (Table 1) [196]. Large HDL2 particles isolated from patients with 
familial hypercholesterolemia (FH) have a reduced capacity to mediate free cholesterol efflux 
via both SR-BI– and ABCG1–dependent pathways [197]. It has also been shown a reduction of 
plasma pre-ß1 HDL, the major acceptor of free cholesterol from cells, in a large cohort of 
patients with type 2 diabetes, which associates with reduced ABCA1-mediated cholesterol 
efflux (Table 1) [198]. Other HDL alterations have been associated to a reduced functionality. 
For example, patients with established CAD have HDL3 particles enriched in specific proteins 
involved in lipid metabolism, complement activation and inflammatory response, such as apoE, 
apoC-IV, apoA-IV and complement C3 (a major effector of the complement system); the 
higher levels of apoE found in HDL3 particles suggests a redistribution of apoE from HDL2 to 
HDL3 with a consequent impairment of the cholesterol efflux capacity in patients with CAD 
[199].  
Other modifications of HDL3 in patients with cardiovascular disease may account for the 
reduced anti-oxidative activity, including a reduced content of PON1 and PAF-AH [177, 200] 
and a reduced phosphatidylcholine/sphingomyelin ratio, which may reflect increased surface 
rigidity [201] (Table 1). 
. HDL modified in vitro as well as HDL isolated from patients with CAD, diabetes, metabolic 
syndrome, chronic kidney disease or acute coronary syndrome fail to stimulate endothelial 
eNOS-activating pathways and NO production [94, 202-204] (Table 1). 
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HDL isolated from patients with stable CAD or acute coronary syndrome (ACS) lose their 
ability to inhibit endothelial cell apoptosis and instead activate pro-apoptotic pathways [135] 
(Table 1). The proteomic analysis of HDL showed a reduction in clusterin and increase in apoC-
III content [135] (Table 1); in agreement cholesterol levels in apoC-III-containing HDL 
particles is positively associated with incident coronary heart disease [205]. In addition, HDL3 
isolated from subjects with the metabolic syndrome exhibit reduced anti-apoptotic properties 
associated to altered physicochemical properties, including core CE depletion and TG 
enrichment [206]. 
 
 
CLINICAL RELEVANCE OF DYSFUNCTIONAL HDL 
Under pathological conditions, HDL can become dysfunctional, independently of their plasma 
levels, due to compositional and functional changes of lipoprotein, as reported in Table 1. For 
example in patients with CAD, diabetes mellitus or chronic renal disease, HDL function is 
impaired [207-209], as they exhibit significantly reduced protective functions, and rather 
acquire pro-atherogenic features [42, 210-213]. Consistently, HDL cholesterol efflux capacity 
is strongly and inversely associated with both subclinical atherosclerosis and obstructive 
coronary disease even when adjusted for HDL-C and apoA-I levels [23].  
Patients with acute coronary syndrome as well as with stable CAD exhibit a reduced HDL-
mediated cellular cholesterol efflux compared with healthy subjects, even when matched by 
HDL-C levels; interestingly, it was reported that the reduction in HDL-mediated cholesterol 
efflux capacity remains impaired also three months later the ACS [196]. ACS is characterized 
by a high degree of inflammation, which results in elevated levels of acute phase proteins such 
as CRP and SAA; thus it is plausible that, during ACS, HDL particles may shift to a pro-
inflammatory profile. In fact, levels of apoA-IV were significantly decreased, while SAA and 
complement C3 were increased in HDL particles of patients with ACS [213], which may alter 
the functions of HDL. Alterations of the HDL proteome has been reported also in subjects with 
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CAD [199, 214]. HDL2 isolated from patients with CAD, whose levels are reduced in patients 
with CAD, also have a higher content of apoC-III (an inhibitor of lipoprotein lipase) and contain 
less apoC-I (which inhibits CETP), which may alter the physiological remodeling of HDL 
particles and lead to the generation of dysfunctional HDL [214, 215].  
Patients with FH are characterized by a large elevation of LDL-C, but other lipid 
abnormalities are present as well. As example, beside the overall lower levels of plasma HDL-
C, also qualitative alterations in this class of lipoproteins has been reported, including the 
enrichment in TG and sphingomyelin, a reduced ability to remove cholesterol from cells, as 
well as reduced anti-inflammatory and anti-oxidant capacities [216]. HDL2 and HDL3 levels are 
reduced compared with control subjects, and large HDL2 particles are less effective in 
promoting cholesterol efflux, probably due to modifications in their phospholipid content [197]. 
An inverse relationship between HDL efflux capacity and development of atherosclerosis in FH 
patients has been observed; specifically, significant inverse relationships between SR-BI–
dependent HDL2 efflux capacity and carotid intima-media thickness and between ABCG1-
dependent HDL2 efflux capacity and carotid intima-media thickness have been observed [197]. 
Of note, TG-enriched HDL3 isolated from FH patients showed a reduced capacity to inhibit the 
release of IL-8 from TNF-α-stimulated endothelial cells, but also the increased content in 
sphingomyelin and saturated fatty acid may contribute to the reduced anti-inflammatory 
activity of HDL3 [201, 217]. Whether these alterations modulate the clinical phenotype of FH 
remains to be investigated. 
A reduced arylesterase activity, catalyzed by HDL-associated PON1, is associated with a 
high systemic oxidative stress; it was shown that in patients with chronic heart failure (HF), 
impaired antioxidant function of HDL (measured as PON1 activity) was associated with adverse 
cardiac events and HF-related hospitalizations[218] as well as with a higher risk of incident 
long-term adverse cardiac events, independent of established clinical and biochemical risk 
factors [219]. In addition, impaired antioxidant function of HDL has been associated with 
premature acute myocardial infarction [220]. The impaired antioxidant activity of HDL was 
observed during the acute phase of acute myocardial infarction (AMI), but also persisted 
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during the stable phase of the disease 1 year after the event [220]. The analysis of HDL 
particle size distribution indicated a reduced number of large HDL particles in patients with 
premature AMI [220]. Furthermore, the correlation of large and intermediate HDL particles 
with antioxidant function observed in control patients was lost in patients with premature AMI, 
which may suggest that the reduction of very large particles and the impaired function of large 
and medium particles might contribute to the pathogenesis of premature acute myocardial 
infarction, thus helping to explain the lost of the inverse relationship between HDL-C levels and 
CV risk in patients with CAD [16]. 
Subjects with type 2 diabetes mellitus (T2DM) have a greater risk of developing 
cardiovascular disease ; this disease is characterized by the presence of the “atherogenic 
dyslipidaemias”, that includes high TG levels, high levels of small dense pro-atherogenic LDL 
and low HDL-C levels [221]. Beside the reduced HDL-C levels, HDL particles from diabetic 
patients are dysfunctional, due to both the presence of advanced glycation end products, and 
to the increased oxidative stress and inflammation that lead to HDL modification and may 
reduce their ability to promote cholesterol efflux [156] or their anti-inflammatory capacity 
[62]. In addition, HDL from type 2 diabetic patients with poor glycaemic control have lower 
antioxidant and anti-inflammatory activities compared with those from patients with good 
glycaemic control [222]. 
Chronic kidney disease is a pathological conditions in which the progressive loss of kidney 
function leads to the worsening of the characteristic dyslipidemic profile, with low plasma 
levels of HDL-C [223]; beside, several other alterations are present in these patients, including 
abnormalities of HDL metabolism, LCAT deficiency, modification of apoA-I, TG enrichment, 
defective cholesterol transport and impaired anti-inflammatory activity [224]. In CKD patients, 
HDL are not able to provide NO to the endothelium to a relevant extent, a mechanism 
dependent on the activation of toll-like receptor 2 [225]. 
As reported for CAD subjects, the inverse association between HDL-C levels and CVD risk is 
significantly attenuated as the glomerular filtration rate (a measure of renal function) 
decreases [209, 226]. The changes in HDL subfractions and their oxidized subfraction particles 
19 
 
are related to the severity of the disease, and higher amount of oxidized HDL may contribute 
to the increased CV risk in patients with advanced CKD [227, 228]. HDL from patients with 
end-stage renal disease on dialysis have a dramatically reduced cholesterol efflux capacity 
compared with matched subjects with normal kidney function, and statin therapy did not 
improve HDL efflux capacity [229]. The HDL anti-inflammatory activity was reduced, but in the 
subgroup of patients on statin therapy it was similar to that of control subjects taking statins 
[229]. The presence of dysfunctional HDL significantly associates with an overall worse 
condition, including significantly higher co-morbidities and a lower quality of life, in 
hemodialysis patients, as suggested by the observation that patients with a higher HDL pro-
inflammatory index have a higher hazard ratio for death than those whose HDL maintain their 
anti-inflammatory properties [230]. 
 
Conclusions 
Atherosclerosis and related diseases, as well as other pathological conditions including acute 
phase reactions and immune diseases, are associated with significant alterations in both HDL-C 
levels and HDL particle structure/composition. Although HDL-C levels inversely correlate with 
the risk of cardiovascular disease, the observation that such relationship is mitigated in 
patients with established cardiovascular disease, together with the findings that very high 
levels of HDL-C do not associate with cardiovascular benefit and even increased the risk of 
CAD, and that pharmacological inhibition of CETP does not translate into a cardiovascular 
benefit despite significant increase in HDL-C levels, limit the relevance of HDL-C levels as an 
index of atheroprotection but rather point toward the investigation of HDL function in 
atherosclerosis . In line with this hypothesis, clinical evidence suggests that high levels of HDL-
C not always are atheroprotective, and instead may mark pro-inflammatory/pro-atherogenic 
features. On the other hand, small peptides that mimic the function of apoA-I render HDL less 
inflammatory [27], promote macrophage reverse cholesterol transport [231] and inhibit LDL 
aggregation [232], and were found to be effective in several animal models of disease [233-
237]. These observations also reveal the limitations of measurements based only on the 
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determination of HDL-C levels. A recent analysis of the JUPITER trial showed that, in patients 
in which the weight of the main cardiovascular risk factor, LDL-C, is significantly attenuated by 
the treatment with a statin, it is possible to highlight the clinical relevance of HDL functionality 
[238]. These results also suggested that pharmacological approaches aimed at increasing HDL-
C plasma levels may not automatically translate into a clinical benefit and instead treatments 
that control hypercholesterolemia/inflammation may also result in an improvement of HDL 
functionality. 
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Table 1. Compositional and functional changes of HDL in pathological conditions 
ACS, CAD HDL-mediated cholesterol efflux [196]; HDL-mediated NO 
stimulation[94]; inhibition of superoxide production [94]; anti-
inflammatory properties and pro-inflammatory properties [94]; 
endothelial repair [94]; PON1 activity [94]; inhibition of endothelial 
apoptosis, pro-apoptotic pathways [135]; clusterin content [135], 
apoC-III content [135, 214]; apoA-IV, SAA and complement C3 
content [213] 
FH HDL-C levels; HDL-mediated cholesterol efflux [197, 217]; 
antioxidant properties [201]; anti-inflammatory activity [201, 217]; 
TG and sphingomyelin content [216] 
T2DM HDL-C levels; pre-ß1 HDL [198]; ABCA1-mediated cholesterol 
efflux[198]; anti-inflammatory properties of apoA-I [62] and HDL 
[222] 
HF HDL inflammatory index [239]; SAA content [239]; PON1 activity 
[218, 239] efflux capacity [200] 
MetS TG content [203], S1P content [203], HDL-mediated eNOS 
activation [203]; anti-oxidative properties [240]; anti-apoptotic 
activity [206]; CE and TG content [206] 
Premature AMI HDL inflammatory index [220]; number of large HDL particles [220] 
CKD HDL2 and HDL3, LCAT and HL deficiency, CETP activity, TG and 
PL content, antioxidant and anti-inflammatory properties, RCT 
[224]; NO production [225] 
Autoimmune 
disease 
cholesterol efflux capacity [186, 188, 189]; antioxidant capacity 
[192]; inflammation [190, 191] 
Acute phase 
reaction 
HDL cholesterol level [183]; cholesterol efflux capacity [183]; SAA 
content in HDL [183]; PON1 and PAF-AH [176]  
CAD, coronary artery disease; ACS, acute coronary syndrome; FH, familial hypercholesterolemia; T2DM, 
type 2 diabetes mellitus; HF, heart failure; MetS, metabolic syndrome; AMI, acute myocardial infarction; 
CKD, chronic kidney disease 
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Legend to the Figures 
Figure 1. Functions of HDL. HDL possess several atheroprotective properties; all these 
activities may be significantly impaired under pathological conditions, due to the generation of 
“dysfunctional” HDL.  
Figure 2. Classification of HDL particles based on their physic-chemical properties. 
Several methodologies exist to separate HDL particles, based on their density, size, charge and 
composition. 
Figure 3. HDL metabolism and remodeling. Pre-β HDL particles acquire cholesterol and 
phospholipids from cells in extrahepatic tissues following the interaction with ABCA1, thus 
generating particles that are more enriched in cholesterol. The enzyme LCAT esterifies the free 
cholesterol molecules to form cholesteryl ester, which migrate within the core of the HDL 
particle forming mature α-migrating spherical HDL particles. These mature HDL particles can 
acquire additional cholesterol following the interaction with ABCG1/ABCG4 transporters. CETP 
mediates the exchange of hydrophobic lipids (CE and TG) between HDL and apoB-containing 
lipoproteins, leading to CE depletion and TG enrichment of HDL. CE is delivered to the liver 
either following the interaction between large HDL and SR-BI or between apoB-containing 
lipoproteins and hepatic LDLR. 
Figure 4. Role of LCAT in HDL metabolism. The free cholesterol acquired by pre-ß HDL 
following the interaction with ABCA1 is esterified by the action of LCAT. LCAT deficiencies lead 
to very low plasma levels of HDL-C and accumulation of pre-ß HDL particles. LCAT, lipoprotein-
associated enzyme lecithin:cholesterol acyltransferase 
Figure 5. Role of CETP in HDL metabolism. CETP reduces circulating levels of HDL-C by 
facilitating the transfer of CE from HDL particles to LDL/VLDL particles in exchange for TG. 
CETP deficiency results in the accumulation of large, cholesterol-rich HDL particles 
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